Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 36 (2), 115-26

Clinical Pharmacokinetics of Meloxicam. A cyclo-oxygenase-2 Preferential Nonsteroidal Anti-Inflammatory Drug

Affiliations
Review

Clinical Pharmacokinetics of Meloxicam. A cyclo-oxygenase-2 Preferential Nonsteroidal Anti-Inflammatory Drug

N M Davies et al. Clin Pharmacokinet.

Abstract

Meloxicam [4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine -3-carboxamide-1, 1-dioxide] is a nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class which shows preferential inhibition of cyclo-oxygenase-2. Meloxicam has a plasma half-life of approximately 20 hours, making it convenient for once-daily administration. Meloxicam is eliminated after biotransformation to 4 pharmacologically inactive metabolites, which are excreted in urine and faeces. Meloxicam and its metabolites bind extensively to plasma albumin. Substantial concentrations of meloxicam are attained in synovial fluid, the proposed site of action in chronic inflammatory arthropathies. Neither moderate renal nor hepatic insufficiency significantly alter the pharmacokinetics of meloxicam. Dosage adjustment is not required in the elderly. Drug-drug interaction studies are available for some commonly co-prescribed medications. Concentration-dependent therapeutic and toxicological effects have yet to be extensively elucidated for this NSAID.

Similar articles

See all similar articles

Cited by 22 PubMed Central articles

See all "Cited by" articles

References

    1. Br J Clin Pharmacol. 1996 Feb;41(2):135-9 - PubMed
    1. Br J Rheumatol. 1998 Sep;37(9):946-51 - PubMed
    1. Br J Clin Pharmacol. 1998 Aug;46(2):133-7 - PubMed
    1. Eur J Clin Pharmacol. 1995;48(3-4):247-51 - PubMed
    1. Neuroreport. 1998 Mar 9;9(4):647-51 - PubMed

MeSH terms

LinkOut - more resources

Feedback